Please assess the completion status of the following clinical trial:

Trial Title: Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 years of age or older, of any ethnic or racial group.~* Diagnosis of cirrhosis or portal hypertension with a serum platelet count less than or equal to 80 × 109/L. \[Rationale: platelet count \<100 × 109/L triples the rate of liver-related adverse events (3) and worsens postoperative survival in the setting of hepatocellular carcinoma (HCC) (4). Initial platelet count of 80 × 109/L can allow the majority of patients who successfully respond to 90Y-RE (clinical endpoint of 50% platelet count increase) to exceed the 100 × 109/L threshold.\]~Cirrhosis is defined by one of three criteria:~* Liver Biopsy/histology consistent with cirrhotic architectural liver changes~* Portal hypertension (Hepatic venous pressure gradient ≥10 mm Hg)~* Evidence of esophageal and/or gastric varices~* Patients must have evidence of splenomegaly as determined by screening cross-sectional imaging.~* No evidence of myelosuppression (e.g. lymphopenia) as evidenced by normal hematology values at Screening~* Adequate baseline organ function(with the exception of cirrhosis) as evidenced by normal BUN/Cr and electrolytes on screening chemistry.~* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2~* Patient has a life expectancy of greater than 6 months without intervention.~* Patient is willing to participate in the study and has signed the study informed consent.~* Women of childbearing potential must have a negative serum pregnancy test within 28 days prior to screening and must not be breastfeeding.~Exclusion Criteria:~* Patients with serum platelet count less than 10 × 109/L.~* History of bleeding disorder attributed to another cause other than cirrhosis (e.g. Von Willebrand disease)~* Declines or unable to provide informed consent~* History of prior partial splenic embolization (PSE) or splenectomy~* Use of any medication known to increase platelet count 1 month prior to Baseline.~* History of allergy or sensitivity to TheraSphere® or its components.~* History of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically~* Contraindications to angiography and selective visceral catheterization such as bleeding, diathesis or coagulopathy that is not correctable by usual therapy or hemostatic agents (e.g. closure device)~* Previous randomization in a trial using 90Y RE~* Patient must not have participated or enrolled in a clinical trial with an investigational device / therapy within 30 days prior to randomization~* Any serious medical condition likely to impede successful completion of the study, such as certain mental disorders, cardiac arrhythmias, and uncontrolled congestive heart failure or respiratory disease.~* Patients actively on chemotherapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Subjects with thrombocytopenia secondary to cirrhosis (Type: EXPERIMENTAL): Evaluate the safety and efficacy of 90Y radioembolization for the management of thrombocytopenia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues